Platelet serotonin and plasma tryptophan were studied in healthy subjects and in depressed patients before and during their antidepressant drug treatment. Before treatment, mean platelet serotonin level was normal in depressed patients compared with healthy subjects while a significant decrease in patients' plasma TRP was noted (t = 6.0, P < .001). anxiety scores. Antidepressant drugs treatment decreased platelet 5-HT level (ANOVA F = B.27, P < .001) whatever the clinical outcome of the patient, whereas the changes observed in plasma TRP were positively related to the mood state change. These results suggest that platelet serotonin could be a good pharmacological model but has no relevance concerning the mood state.
Following the discovery that blood platelets accumu late serotonin (about 99% of total blood serotonin [5-HT] levels) due to their powerful uptake and storage mech anisms similar to those of central neurons (Stahl 1977) , a large number of studies have examined the serotonin function of the blood platelet in various pathological conditions such as autism (Cook 1990) , alcoholism (Bailly et al. 1990) , and affective disorders (Quintana 1992) . Clinical results from these different studies have anxiety scores. Antidepressant drugs treatment decreased platelet 5-HT level (ANOVA F = B.27, P < .001) whatever the clinical outcome of the patient, whereas the changes observed in plasma TRP were positively related to the mood state change. These results suggest that platelet serotonin could be a good pharmacological model but has no relevance concerning the mood state. [Neuropsychopharmacology 10:207-214, 1994J confirmed that blood platelet could be a convenient pe ripheral model for serotonin studies, and the advan tage of its ease of preparation has contributed to popu larize the use, with some limitations, of the platelet model (Pletscher and Laubscher 1980) .
In affective disorders, attempts to determine the in volvement of serotonin mechanisms have mainly fo cused on platelet 5-HT receptors (Arora and Meltzer 1989) , 3 H-imipramine binding (Langer and Briley 1981) , and on the uptake mechanisms (Malmgren et al. 1981) , where most of investigations have reported abnormali ties. Very few studies have examined depression-asso ciated changes in platelet 5-HT levels, and investiga tions in this domain have mostly yielded contradictory results (Lingjaerde 1979) . For example, Muck-SeIer et al. (1991) have recently reported a hyperserotonemia in unipolar depressed patients, whereas Quintana (1992) found a decreased platelet 5-HT content in ma jor depressed patients. The same author also reported an increase of platelet 5-HT concentrations following imipramine treatment, whereas previous papers had often reported that imipramine or other tricyclics (Mar tensson et al. 1991; Celada et al. 1992 ) induced platelet 0893-133X/94/$7.00 5-HT depletion, whatever the clinical outcome. How ever, although early results from Wirz-Justice and Piihringer (1978a) reported an increase of platelet 5-HT in bipolar patients with no change in unipolar patients' platelet 5-HT levels, most later investigators (Sarrias et a1. 1987 ) reported a decreased platelet 5-HT in melan cholic patients, supporting the hypothesis that patho physiology of some subtypes of depression is associated with serotonergic dysfunction (Coppen and Doogan 1988; Meltzer 1989 ) that could be also detected at the periphery. Nevertheless, blood 5-HT levels vary accord ing to multiple physiological and pathological factors (Guicheney et al. 1988) and environmental factors such as photoperiod, season, or temperature (Sarrias et a1. 1989) . Moreover, although the central 5-HT originates exclusively from tryptophan directly decarboxylated by the enzymatic cell mechanisms, the platelet 5-HT ori gin is heterogenous, the enterochromaffm cells and the liver being the most important sources, rendering the platelet 5-HT levels sometimes inconsistent (Osim and Wyllie 1991) .
With respect to plasma tryptophan (TRP) and affec tive disorders, a large number of studies were reported during the last two decades (Wood et a1. 1978; Cowen et a1. 1989) , as the brain 5-HT was shown to depend on the plasma aminoacid precursors which cross the blood-brain barrier (Fernstrom 1983) . Tryptophan cir culates in blood plasma in two main forms, one free and one bound to plasma albumin. Changes in the plasma levels, free and total forms, have been described (Moller et al. 1979; Guicheney et al. 1988) . The plasma TRP has been associated with mood changes (Young et al. 1988) , and decreased plasma total TRP levels were previously reported in this laboratory (Bovier et al. 1988) . It was thus suggested by some that, as a conse quence of changes in plasma TRP levels, an altered amount of 5-HT occurs in brain and platelets (Quintana 1992) . In spite of this suggested functional link of plasma TRP levels and functional serotonergic mechanisms in depression, no study has up to now successfully es tablished a correlation between plasma TRP and plate let 5-HT levels.
The aim of this study was to provide additional data on platelet 5-HT and plasma TRP and to reassess the platelet 5-HT levels status in depressive syndromes and its relationships with plasma TRP, a subject that has received little attention. As longitudinal studies are re quired in studying relationships between biological vari ables and psychopathology, in a follow-up study we have investigated the correlations between serotoner gic parameters, ATD drugs, and the change of mood. Lastly, comparisons between the effects induced by different classes of drugs were performed to complete our information in this subject. NEUROPSYCHOPHARMACOLOGY 1994-VOL. 10, NO. 3 
MATERIALS AND METHODS

Subjects
Thirty depressed patients (20 F; 10 M) with mean age of 47 ± 10 years participated, with their consent, in this study. They met the criteria of DMS-III-R for depres sive syndromes (24 major depression patients) recur rent or unique episode (293.6X); 3 bipolar depressed (296.5X) and 3 dysthymic patients (300.40) and were without any physical illness. At their hospitalization, patients first underwent a drug washout period of a minimum of two weeks (14 to 26 days) before biochem ical analysis.
The severity of depression was evaluated by two experienced clinicians using the AMDP depression rat ing scale (Bobon 1981) before treatment (TO) and after one month (Tl), two months (T2), and three months (T3) of treatment. At the same time, the clinicians rated the severity of anxiety with the AMDP anxiety scale (Bo bon 1981). At each time (TO, Tl, T2, T3) patient's blood was collected and biochemical analysis, consisting of platelet serotonin and plasma tryptophan, was carried out. Only 28 patients receiving drug treatment were followed-up during the entire period of three months.
The treatment consisted of the various antidepres sant drugs (ATD), randomly given in a daily dose of 150 mg of imipramine to 12 patients; 300 mg of fluvox amine to two patients; 20 to 40 mg fluoxetine to three patients; 600 mg of moclobemid, a reversible mono amine oxidase inhibitor, to three patients; 250 mg of maprotiline to three patients; and 150 mg of amitripty line to £lve patients.
Twenty subjects (10 F; 10 M) who served as con trols in this study were in good physical health; they had no history of mental disorder, neurological disease, or drug abuse. Their mean age was 47 ± 9 years, the same as that of the patients.
Blood Sampling
Blood (9 ml) was drawn by venipuncture from the ante cubital vein in 10-ml tubes containing 1 ml of an ticoagulant (ACD, 0.06 M citrate-Na; 0.038 M citric acid and 0.136 M dextrose). Blood collection was always per formed in morning between 8 and 9 A.M., and the plate let rich plasma (PRP) was isolated within 30 minutes by centrifugation (160 g x 10 minutes) at 4°C. A small aliquot (100 ml) was taken to count the platelet number.
For the study of platelet 5-HT, the PRP was cen trifuged again at 5100 g x 10 minutes to pellet plate lets. The platelets were resuspended in a washing buff er (50 mM Tris-HCl) and washed before another spin at the above speed. Then the pelleted platelets were lysed in 0.1 M H 3 P04 by sonication and centrifuged again. and patients gave significant differences in plasma TRP and in platelet count.
* t = -2.31, P < .03. *** t = 6.00, P < .001.
The supernatant was isolated and injected in a HPLC apparatus with an electrochemical detector set at 0.72 mv of potential. Results were expressed in ng/109 platelets.
For the plasma tryptophan study, the platelet poor plasma (PPP) was isolated either from PRP or from whole blood by centrifugation at 5100 g x 10 minutes at 4°C. 0.1 ml plasma was deproteinezed with 1.1 mmollL perchloric acid (0.85 ml), neutralized with 15 N KOH (0.05 ml) then centrifuged, and the supernatant was injected in a HPLC apparatus with a UV -Visible detector set at 206 nm. Tryptophan was coeluted with other neutral aminoacid, phenylethylamine, and tyro sine on the same chromatograph. Results were ex pressed in mg/ml plasma. The statistical analysis was performed using a two-way ANOV A between groups, followed by Student t test, and in some cases regres sion analysis was performed for the calculation of corre lations between parameters. Statistical signifIcance was set at p < .05. Table 1 shows the mean values of platelet 5-HT levels and plasma TRP levels in drug-free depressed patients. With respect to platelet 5-HT level there was no signifIcant difference between patients and control subjects (t test t = .67, NS). For plasma TRP, patients presented signifIcantly decreased values compared to controls (t test t = 6.0, P < .001) and a low platelet count (t test t = 2.13, P < .03) ( Table 1 ). The exclusion of non unipo lar patients did not change the results because no differ ence was observed in the diagnostic groups.
RESULTS
Although a tendency for male subjects to present relatively higher TRP levels than females was previously reported, the difference between both sexes was not signi&cant in this population. In normal controls the TRP mean value (X ± SEM) was 12.15 ± 0.5 Jlg/ml and 11.68 ± 0.5 Jlg/ml for males and females, respectively (t test was 1.01, NS) and in patients, the mean value was 8.67 ± 0.4 Jlg/ml and 8.32 ± 0.4 Jlg/ml (t test was 0.93, NS) for males and females, respectively.
Furthermore, the analysis of other neutral amino acids revealed no signifIcant difference between pa tients and controls. Plasma tyrosine mean (X ± SEM) level was 11.26 ± 0.3 Jlg/ml and 10.92 ± 0.3 Jlg/ml (t test: NS) for controls and patients respectively. Plasma phenylalanine mean (X ± SEM) level was 9.16 ± 0.4 Jlg/ml in controls versus 9.52 ± 0.5 Jlg/ml in depressed patients (t test: NS).
Correlations between biochemical and clinical vari ables were calculated, and the results are summarized on Table 2 . Platelet 5-HT levels did not correlate with either plasma TRP or clinical parameters (r = .18, NS, Plasma TRP (c) (�g/ml) 8.57 ± 0.3 9.93 ± 0.4* 10.14 ± 0.5* 10.31 ± 5* AMDP depression (d)
22.3 ± 1. 8
12.9 ± 2*** 11.7 ± 2*** 9.16 ± 2. 0*** AMDP anxiety (e)
5. 36 ± 0. 5 3.42 ± 0.5* 3.88 ± 0.6 2.14 ± 0.4** Thirty depressed patients were examined at TO, but only twenty-eight of them were examined during the treatment period. Statistical comparisons were performed with a two-way ANOVA for each parameter between different times (TO to T3) of study, fol lowed by the Student t test between the different treatment values, with respect to the pre-treatment value (TO): * p < .05, ** P < .001, *** P < .001. ANOVA: (a) F = 8.27, P < .001; (b) F = 0.6, NS; (c) F = 2.14, P < .05; (d) F = 6.29, P < .001; (e) F = 4.51, P < .001. and r = .03, NS for depression and anxiety, respec tively), and no effects of age (r = .19, NS) or sex were evident. Similarly, plasma TRP did not correlate to the AMDP depression (r = .02, NS), anxiety (r = .OS, NS), age (r = .31, P < .07), and sex ( Table 2 ).
Changes that occurred during the period of ATD drug treatment in platelet S-HT levels and in plasma TRP were measured (Table 3) . From TO to T3, platelet S-HT levels underwent a drastic decrease (ANOV A: F = 8.27, P < .001) whereas plasma TRP slightly increased during the same period (ANOV A: F = 2.14, P < .OS). The clinical parameters (AMDP depression and AMDP anxiety mean scores) also signilicantly decreased in the same period (ANOV A F = 6.29, P < .001 and F = 4.S1, P < .001, respectively). In the fIrst month of treatment (Tl), about SO% of platelet S-HT level was depleted (t test t = 3.09, P < .0001), and AMDP depression score was approximately decreased by SO% (t test t = 3.36, P < .001). After three months, the platelet S-HT levels represented only about lS% of the pretreatment value (t test t = 4.07, P < .001), and AMDP depression and anxiety had progressively decreased. The plasma TRP level increased modestly and did not reach the control values. No change was observed in platelet number during the follow-up period (ANOVA F = 0.6, NS).
The clinical outcome and the effect of drugs on bio chemical parameters were examined to understand the changes observed in platelet S-HT level and in plasma TRP. With respect to clinical outcome, Figure 1A shows that no difference was observed in the evolution of platelet S-HT. In both improved (more than SO% change in AMDP depression score) and nonimproved (less than SO% change in AMDP depression score), the de crease in platelet S-HT was the same, whereas plasma TRP ( Figure 1B) increased only in improved patients (ANOVA: F = 3.62; P < .002 and F = 1.S; NS). The difference in AMDP anxiety score between improved and nonimproved patients was also signifIcant, and the change was only observed in improved patients (F = 6.7; P < .001 and F = 1.S; NS for improved and nonimproved, respectively). Improved patients were less anxious than nonimproved subjects (t test: p < .01) (Fig. 1C) .
To investigate the effects of drugs on platelet S-HT changes, the different antidepressants used in the treat ment were grouped in four categories: selective S-HT blockers (fluoxetine and fluvoxamine); b-selective NA blockers (maprotiline); mixed S-HT/NA blockers (im ipramine, amitriptyline); and monoamineoxidase inhib itors (moclobemid). Figure 2 shows that important change occurred in platelet S-HT of patients treated with serotonergic or "mixed" drugs whereas no change was observed in NA blockers drugs (ANOV A F = 14.06; P < .001 and F = 12.06; P < .001 for the "mixed" and the serotonergic drug group, respectively). In contrast, the patients who were treated with moclobemid (a MAOI) or mapropotiline (a noradrenergic drug) did not signilicantly change their mean values during the treat ment period (AN OVA F = 0.17, NS and F = 0.3, NS for MAOI-and moclobemid-treated patients, respec tively). Yet a small increase of platelet S-HT level was observed at Tl in the MAOI-treated group (the non parametric Wilcoxon test yielded Z = -2.02; P < .04).
DISCUSSION
The present study indicated fIrst that platelet S-HT con tent was not different in drug-free depressed patients, compared to normal controls, whereas plasma TRP lev els were signifIcantly decreased in patients. Further more, no diff erence was observed in male and female subjects, both in controls and patients group of this population with respect to their plasma TRP level. The other plasma neutral aminoacids, that is, phenylalanine and tyrosine, co-analyzed with TRP did not present any difference between normal controls and patients.
Second, both serotonergic indices (i.e., platelet S-HT levels and plasma TRP) did not correlate either with each other, in spite of their precursor-metabolite affiliation, or to clinical rating scores (i.e., AMDP depression and anxiety). Third, serotonergic and "mixed" NA/5-HT ATD drugs treatment induced a marked decrease in platelet 5-HT stores, independently of the clinical outcome, whereas plasma TRP changes were associated to the mood state changes. Moreover, it should be mentioned that no difference in platelet 5-HT or plasma TRP was found between male and female subjects, and no effect of age was detected in accordance to previous reports (Stahl et al. 1983) .
The lack of change in platelet 5-HT level of de pressed patients observed in this study was at variance with some previous studies (Le Quan-Bui et al. 1984 , Sarrias et al. 1987 , or Quintana 1992 ) that reported a decrease in platelet 5-HT content in major depression. The reason for this discrepancy is unclear. Several fac tors are involved in the control of the platelets store, Platelet 5-HT and Plasma TRP 211
Figures 1. Changes in platelet 5-HT levels (A), plasma tryp tophan (B) and AMDP anxiety scores (C) with respect to clin ical improvement. Improvement in depression was arbitrar ily set at >50% of AMDP depression score decrease. Statistical analysis was performed with a two-way ANOV A followed by a Student t test to compare improved and non-improved patients or drug treated to drug-free patients. The test of ANOVA for both groups with regard to 5-HT: F = 5.68, P < .001 and F = 4.89 P < .001 for improved and nonimproved patients respectively (A), with regard to plasma TRP: F = 3.62; p < .02 and F = 1.51; NS for improved and nonimproved respectively (B) and with regard to AMDP anxiety change: F = 6.71; P < .001 and F = 1.53; NS for improved and non improved respectively (C). Student t test between improved and nonimproved: **p < .01; ***p < .001. Student t test be tween drugs treated (Tl to T3) to drug-free (TO) patients: A, p < .05; B, p < .01; C, P < .001.
such as the uptake mechanism by platelet membrane, the storage processes in dense granules, the process of release, and the intracellular conjugation or degra dation of the amine (Le Quan- Bui et al. 1983 ). Any al teration in the above factors should affect platelet stores; indeed the uptake mechanism was observed by most (Tuomisto and Tukiainen 1976, Malmgren et al. 1981) but not all investigators (Stahl et al. 1983 ) to be de creased in platelets from unipolar depressed patients. However, there are also reports at variance with the depression-associated reduction of platelet 5-HT level. Wirz-Justice and Puhringer (1978a) have found an in crease in bipolar patients without alteration in absolute platelet 5-HT levels from unipolar patients, and those results were later replicated by Stahl et al. (1983) . Moreover, the study from Muck-SeIer et al. (1991) was also at variance with the reduced platelet 5-HT level in endogenous depression (Muck-SeIer et al. 1991 ). These authors reported a hyperserotonemia in major depres sion. The results indicate that the status of the platelet 5-HT level is not yet clear. Differences resulting in non homogeneity of patient groups and assay problems related to platelets preparation cannot alone account for those inconsistent fIndings. According to Ortiz et al., the blood contains two different pools of serotonin, the plasma 5-HT, in nanomolar concentrations, which is a rapid turn-over pool more affected by short-term variations in 5-HT physiology, and the platelet 5-HT in micromolar concentrations, which constitutes a re serve with a slow turnover pool and sensitive to more sustained changes (Ortiz et al. 1988) . Future results will indicate which of those blood serotonergic pools would be more functionally linked to psychopathological states. With regard to plasma TRP, our study has found lowered level in depression with a tendency to normal ize in drug treatment responders. This reduced plasma TRP in depression was previously reported by others (Coppen et al. 1973; Cowen et al. 1989) . In drug responders, the observed increase of plasma TRP could be attributed to the recovery of the mechanisms of aminoacid synthesis. But paradOxically, this newly syn-NEUROPSYCHOPHARMACOLOGY 1994-VOL. 10, NO.3 thesized TRP was not reflected in the platelet 5-HT con tent. This is due to the presence of antidepressant drugs. However, other neutral aminoacids (NAA) have been shown to compete with TRP in transport mem brane, and the ratio of TRP to the NAA, especially tyro sine and phenylalanine, could influence the synthesis of 5-HT (Wurtman and Fernstrom 1972; Acwort et al. 1988) . Plasma TYR and PHE have been measured in the present study, and no change was found between en dogenous depressed patients and normal controls. Moreover, as we showed previously, plasma TYR and PHE levels did not change during a six-week period of drug treatment (Chiaroni et al. 1990 ). Thus, the proba bility that these aminoacids influenced the synthesis of 5-HT is very low, but caution must be taken, as all of the NAAs (i.e., leucine, isoleucine and valine) have not been measured.
In addition, the plasma TRP level did not increase the normal values, and in this sense it would resemble other serotonergic parameters like 3 H-imiprarnine bind ing (Langer and Briley 1981) , and CSF 5-HIAA (Trask man- Bendz et al. 1984) . Thus, the lack of correlation between platelet 5-HT and plasma TRP and the lack of effect of plasma TRP changes on platelet 5-HT render questionable the relevance of platelet 5-HT in depres sion. Studying the source of serotonin in blood, Pietraszek et al. have recently reported that brain 5-HT was correlated to both blood and brain TRP pools, whereas 5-HT was not (Pietraszek et al. 1992) . The blood serotonin was only correlated to that in stomach; this could partially explain the above results.
The drastic decrease observed in platelet 5-HT level under "mixed" (imipramine and chlomipramine) and serotonergic drugs (fluvoxamine and fluoxetine) is in agreement with previous reports (Celada et al. 1991; Sarrias et al. 1989 ) and should be interpreted as a con sequence of the action of these drugs in inhibiting the uptake of 5-HT levels. The entry of 5-HT into the cell is still blocked by the presence of A TO and conversely, newly formed platelets contain very low levels of the amine. Moreover, this decrease was of the same extent in both drug-responders and nonresponder patients. As in the above result, this point reinforces the doubt about the relevance of the platelet 5-HT levels in depres sion. It could point out, a pharmacological action of the antidepressants, however, specifIcally drug-associated as no decrease was observed in the nor adrenergic-drug (maprotiline)-treated patients. Thus, platelets would be a good index of the pharmacological effIcacy in regard to 5-HT uptake. The inhibition of amine oxidation (with moclobemid), as expected, induced a slight increase at T1 in the platelet 5-HT content. This indicates that, in the absence of blockers with a serotonergic action, mechanisms of 5-HT entering the cell were still work ing, and the inhibition of oxidation contributed to the relative increase in the amine level. The results are com-parable with brain studies where it was reported that long term re-uptake inhibition, but not monoamine ox idase inhibition, actually decreases the 5-HT function (Blier et al. 1988 ).
In conclusion, this study has noted a decreased plasma TRP with no change in platelet 5-HT level in depressed patients. Although both measures were not correlated to depression severity or to anxiety scores, plasma TRP was more associated with depressive state than was platelet 5-HT because it changed in relation to depression severity and it trended to normalization in ameliorated patients only. ATD drugs induced a change in platelet 5-HT level specifIcally related to the mode of drug action, and this could be of pharmaco logical signifi.cance.
